arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 132605 |
| CHEMBL ID | 87188 |
| MeSH ID | M0219758 |
| Synonym |
|---|
| CHEMBL87188 , |
| bdbm50039573 |
| 2-[1-[1-amino-4-amino(imino)methylamino-(1s)-butylcarboxamidomethylcarboxamido]-2-carboxy-(1s)-ethylcarboxamido]-3-(1h-3-indolyl)-(2s)-propanoic acid |
| arginyl-glycyl-aspartyl-tryptophan |
| 144161-76-2 |
| d-arg-gly-asp-trp |
| l-tryptophan, n-(n-(n-d-arginylglycyl)-l-alpha-aspartyl)- |
| rgdw peptide |
| d-rgdw |
| drgdw |
| DTXSID90162626 |
| (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-(1h-indol-3-yl)ethyl]amino]-4-oxobutanoic acid |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | IC50 (µMol) | 16.5667 | 0.0001 | 0.6323 | 10.0000 | AID161600; AID217295; AID84830 |
| Integrin beta-1 | Homo sapiens (human) | IC50 (µMol) | 27.0000 | 0.0001 | 0.7252 | 8.0000 | AID221747 |
| Integrin alpha-V | Homo sapiens (human) | IC50 (µMol) | 24.0000 | 0.0001 | 0.6256 | 10.0000 | AID217295; AID84830 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 (µMol) | 1.7000 | 0.0001 | 0.7309 | 10.0000 | AID161600 |
| Integrin alpha-5 | Homo sapiens (human) | IC50 (µMol) | 27.0000 | 0.0001 | 1.4082 | 8.0000 | AID221747 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID161600 | Inhibition of platelet aggregation as the concentration necessary to inhibit the change in light. | 1994 | Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16 | Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. |
| AID84830 | Inhibition of human umbilical vein endothelial cell adhesion to fibrinogen | 1994 | Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16 | Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. |
| AID221747 | Inhibition of human umbilical vein endothelial cell adhesion to fibronectin | 1994 | Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16 | Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. |
| AID217295 | Inhibition of human umbilical vein endothelial cell adhesion to vitronectin | 1994 | Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16 | Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||